Market Access/ Views & Analysis/ Views and analysis Market access roundup: Government grillings for Vertex and US pharma George Underwood Catalyst, cystic fibrosis, pricing, Roundup, Vertex 0 Comment It was a month characterised by governments butting heads with pharma over pricing both in the UK and Share X Market access roundup: Government grillings for Vertex and US pharma https://pharmaphorum.com/views-analysis-market-access/market-access-roundup-government-grillings-vertex-us-pharma-pricing/
News/ News/ Patients/ Top stories Sanders calls on FDA to allow low-cost rivals to $375k Catalyst drug Phil Taylor Bernie Sanders, Catalyst, Firdapse, rare disease 0 Comment US Senator Bernie Sanders says the FDA should allow pharmacies and generic manufacturers to make low-cost copies of Share X Sanders calls on FDA to allow low-cost rivals to $375k Catalyst drug https://pharmaphorum.com/news/sanders-calls-on-fda-to-allow-low-cost-rivals-to-375k-catalyst-drug/
News Catalyst sparks price row in US with $300,000 rare disease drug Richard Staines Catalyst, Firdapse, pricing, Rare diseases 0 Comment The controversy over rising drug prices in the US has been reignited after it emerged that the yearly Share X Catalyst sparks price row in US with $300,000 rare disease drug https://pharmaphorum.com/news/catalyst-sparks-price-row-in-us-with-300000-rare-disease-drug/
Catalyst, cystic fibrosis, pricing, Roundup, Vertex
0 Comment
